What is Innoforce Pharmaceuticals?
Innoforce Pharmaceuticals is a partnership-focused biopharmaceutical company dedicated to accelerating the development of breakthrough medicines. Leveraging world-class biopharmaceutical manufacturing and development capabilities at its campus in Hangzhou, China, and offices in Rockville, Maryland, Innoforce offers end-to-end contract development and manufacturing services (CDMO). Their expertise spans GMP manufacturing of plasmid DNA, RNA, viral vector, and cell products, alongside CDMO services for antibody and protein drugs through a joint venture. Innoforce's enabling capabilities are designed to support partners and portfolio companies in rapidly bringing cutting-edge cell, gene, and advanced biological therapies to global markets, impacting patients' lives worldwide.
How much funding has Innoforce Pharmaceuticals raised?
Innoforce Pharmaceuticals has raised a total of $156.6M across 1 funding round:
Series A
$156.6M
Series A (2021): $156.6M with participation from Advantech Capital, China Highrun Capital, and South China Venture Capital
Key Investors in Innoforce Pharmaceuticals
Advantech Capital
Advantech Capital is a private equity fund established in 2016, focused on innovation-driven growth capital in China, with interests in TMT, E-services, and Healthcare.
China Highrun Capital
China Highrun Capital Limited focuses on Private Equity investments, Merger & Acquisitions, and financial advisory services, investing across various sectors including Medical and IT, from start-up to Pre-IPO stages.
South China Venture Capital
South China Venture Capital (SCVC), established in 2008, manages RMB and USD funds for early to growth-stage investments in biomedicine, semiconductors, and AI, aiming to empower technology with capital.
What's next for Innoforce Pharmaceuticals?
The substantial enterprise-level backing Innoforce Pharmaceuticals has received, highlighted by its recent strategic investment, positions the company for significant expansion and further development of its CDMO services. This capital infusion is expected to fuel advancements in manufacturing technologies and capacity, enabling Innoforce to solidify its market position and support a growing pipeline of innovative therapies. The company's focus on partnership and end-to-end solutions suggests a strategic direction aimed at becoming a key enabler for biopharmaceutical innovation globally, particularly in the rapidly evolving fields of cell and gene therapy.
See full Innoforce Pharmaceuticals company page
